Search Results for keywords:"section 529 FD

The Food and Drug Administration (FDA) is updating the definition of the term "healthy" as it applies to food labeling to align with current nutrition science and dietary guidelines. This new rule outlines what food manufacturers must meet to label their products as "healthy," focusing on food groups and limiting certain nutrients like added sugars, saturated fats, and sodium. The rule aims to help consumers make better choices for maintaining a nutritious diet and to reduce diet-related chronic diseases. It is designed to ensure that foods labeled as "healthy" provide accurate and helpful information, promoting overall health and nutrition equity.

The Unified Carrier Registration (UCR) Plan Board of Directors is seeking nominations for a motor carrier industry position on the Board. Candidates must represent a motor carrier within the smallest fleet fee bracket. The chosen individual's term will start immediately and run until May 31, 2027. Nominations, including resumes, must be received by May 12, 2025. The appointment decision rests with the Federal Motor Carrier Safety Administration (FMCSA), which may consider recommendations from the Board.

The Federal Energy Regulatory Commission (FERC) has received several electric rate filings and proposed changes from various applicants, including Sweetland Wind Farm, LLC, and PJM Interconnection, L.L.C. These filings include requests for market power analysis, new service agreements, and tariff amendments. The documents outline the effective dates, filing dates, and deadlines for comments or protests. People interested in participating or learning more about these proceedings can access the filings online or contact FERC for assistance.

The Food and Drug Administration (FDA) has made changes to rules about animal drugs to update new and existing drug applications, improve readability, and ensure accurate information. These updates reflect approvals, withdrawals, and sponsorship changes for animal drugs from July to September 2024. The FDA also amended its regulations to communicate these changes and to clarify the information about sponsors and conditions of use for drugs. This rule is effective as of December 2, 2024.

The National Park Service is asking for public comments on the significance of various properties that were nominated before March 1, 2025, for listing in the National Register of Historic Places. They are accepting electronic comments until April 1, 2025. The notice provides details on specific properties across several states, including California, Colorado, Florida, Iowa, Kansas, Michigan, Missouri, Ohio, Pennsylvania, Puerto Rico, Tennessee, Virginia, and Wisconsin. Additionally, the document mentions requests for the removal of certain resources and additional documentation for others.

Puerto Verde Industrial Railroad, LLC (PVIR), a noncarrier company, plans to operate a 2.43-mile private railroad track in Maverick County, Texas, on the site of a former coal mine. This site, owned by PVIR's affiliate, Farming Hydrasource, LLC, is being converted into an industrial park. Once operational, PVIR will provide carrier services like switching and transloading for local businesses. The railroad's annual revenue is projected to stay under $5 million, classifying it as a Class III rail carrier. The earliest start date for operations under this exemption is January 1, 2025, and certain regulatory reviews do not apply to this project.

The Food and Drug Administration (FDA) has calculated the regulatory review period for the human drug product VEOZAH, which is used to treat menopause-related symptoms. This review period consists of 2,573 days, split between the drug testing phase (2,248 days) and the approval phase (325 days). The announcement is necessary due to requests for patent term extensions filed with the U.S. Patent and Trademark Office. The FDA invites comments and petitions regarding the accuracy of these dates and the diligence of the applicant during the review process.

The Food and Drug Administration (FDA) has determined the regulatory review period for the drug XTAMPZA ER, which is used for managing severe pain requiring long-term opioid treatment. This review is necessary for a possible extension of the drug's patent, as requested by Collegium Pharmaceutical, Inc. The review period comprises 3,214 days, with 2,712 days for testing and 502 days for approval. The FDA invites comments on this determination and allows for petitions if there are disagreements concerning the information or the due diligence during the review process.

The Food and Drug Administration (FDA) has announced its determination of the regulatory review period for the human drug BYLVAY. The FDA made this determination following a request from the U.S. Patent and Trademark Office for information related to patent term restoration. BYLVAY, approved for treating pruritis in patients aged 3 months and older with progressive familial intrahepatic cholestasis, underwent 1,868 days of regulatory review, including a testing phase of 1,625 days and an approval phase of 243 days. This notice invites anyone with information suggesting that these dates might be incorrect to submit their comments for consideration.

Union Pacific Railroad Company (UP) has reported that it has gained temporary rights to use a section of track owned by BNSF Railway Company. This particular agreement allows UP to transport ballast trains, which are used for maintenance work, over a 51.7-mile stretch of rail in Oklahoma and Texas. The temporary rights will last until the end of 2021, and UP has stated that these actions are exempt from environmental and historical preservation reviews. If anyone believes this notice contains false information, they can petition to revoke the exemption, but such petitions will not delay the exemption's start date unless filed by a certain deadline.